A serious complication of aplastic anemia (AA) is its evolution to clonal hematologic diseases such as myelodysplasia (MDS) and leukemia, which is usually associated with the appearance of a cytogenetic abnormality in bone marrow cells. We present here an analysis of a cohort of 30 patients with otherwise typical AA in whom clonal karyotypic evolution was observed during frequent periodic marrow examinations. The actuarial risk for this complication has been estimated in other studies at around 15% at 5 years. Conversion from normal to abnormal karyotype occurred at a constant rate after initial diagnosis, with about 50% of cases developing within the first 30 months. Transient chromosomal abnormalities were infrequent. Clinically, AA patients with clonal cytogenetic patterns were heterogenous; a variety of karyotypic defects with numerical and structural abnormalities of chromosome 7 accounted for 40% of all cases followed by trisomy 8, structural and numerical abnormalities of chromosome 13, deletion of Y chromosome, and complex cytogenetic abnormalities. Unlike in primary MDS, aberrancies of chromosome 5 and 20 were infrequent. The clinical course depended on the specific abnormal cytogenetic pattern. Most deaths related to leukemic transformation occurred in patients with abnormalities of chromosome 7 or complex cytogenetic alterations or both. Evolution of chromosome 7 abnormalities was seen most often in refractory patients who had failed to respond to therapy. In contrast, trisomy 8 developed in patients with good hematologic responses who often required chronic immunosuppression with cyclosporine A (CsA), and survival was excellent. Although AA patients with monosomy 7 showed a similar prognosis to those with primary MDS, trisomy 8 in AA appears to have a more favorable prognosis than in MDS.

With the introduction of immunosuppressive therapy (IST) for aplastic anemia (AA), the survival of patients who are not treated with bone marrow (BM) transplantation has improved significantly.1 However, with long-term systematic observation, evolution of AA to other hematologic diseases has been frequently recognized as a serious late sequelae of this disease. Historically, paroxysmal nocturnal hemoglobinuria (PNH) was considered the most common clonal complication, but its incidence is now appreciated to be high at initial presentation of AA.2,3The second most common clonal disease occurring in the context of AA is myelodysplasia (MDS). Aberrant maturation, increased numbers of myeloblasts, and marrow hypercellularity are all characteristic of MDS, but persistent marrow hypocellularity in AA may preclude reliable morphologic analysis. The finding of a cytogenetic abnormality therefore is the most objective evidence of clonal evolution.

The acquisition of an abnormal karyotype in the setting of diagnosed AA is not infrequent, but estimates have been variable among published studies, due to differences in diagnostic criteria, patient populations, treatment protocols, and the frequency of follow-up BM examinations.4-15 In an early study from Seattle, an abnormal karyotype acquired in the course of the disease was reported in 3 of 183 AA patients.9 In a recent European analysis, abnormalities occurred in 23 of 170 patients, but in 4 cases, chromosomal changes were present at first diagnosis.6 In another report of 69 Italian AA patients, an abnormal karyotype was found in 18, but the findings were transient in 8 patients and in only 7 cases was the karyotypic abnormality known not to be present initially.8 Similarly, in a recent series of 13 patients with AA and abnormal cytogenetics, only 2 developed the abnormality later in the course of the disease.7 Of 40 Japanese children treated with granulocyte colony-stimulating factor (G-CSF) and cyclosporine A (CsA), cytogenetic evolution was found in 11.11 At our institution, abnormal cytogenetics excludes a diagnosis of AA, regardless of marrow morphology; in our National Institutes of Health (NIH) series of 122 patients treated with intensive immunosuppression, 14 have developed karyotypic abnormalities, with a risk of about 21% at 10 years.6 In a preliminary combined analysis of 189 patients treated with various immunosuppressive regimens on consecutive protocols, the actuarial risk of karyotypic conversion was estimated at 14% at 5 years and 20% at 10 years (J.M., unpublished observation).

Based on our stringent initial diagnostic criteria, the new appearance of a karyotypically abnormal clone has warranted a change of diagnosis from AA to MDS. To avoid observer bias, we purposely selected karyotype rather then morphologic criteria in our case definition. Using this approach, we could determine the clinical features and prognosis of patients who developed abnormal cytogenetics in the course of their AA.

Patients

Patients with either AA evaluated or treated (or both) in the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI, Bethesda, MD) were studied. Informed consent for the laboratory tests and clinical examination was obtained according to protocols approved by the Institutional Review Board of the NHLBI.

Case definitions and diagnostic criteria

We designed an observational study to determine the clinical features and outcomes associated with the development of new cytogenetic abnormalities in patients with a history of AA treated with immunosuppressive drugs. Our case definition included: (1) an initial diagnosis of AA (see below) and normal karyotypic analysis at the time of diagnosis (patients for whom such an analysis was not obtained at the time of presentation or in which the study was not informative were excluded, and (2) new appearance of a karyotypically abnormal clone defined as 2 or more metaphase cells with the same extra chromosome(s) or structural rearrangement(s) or 3 or more cells with the same missing chromosome. The minimum number of cells to be analyzed in each BM was 20, provided there were that many present. Complete medical histories were available in all cases. For patients participating in treatment protocols at NIH karyotypic analysis was routinely performed at presentation, at 6 months, and at 1 year after IST and then annually. In addition, cytogenetic studies were performed for clinical indications, such as the appearance of circulating blasts or worsening blood counts. Patients who did not participate in NIH treatment protocols also fulfilled the above described diagnostic criteria, and their abnormal karyotype was confirmed at the NIH.

The diagnosis of AA was established by BM biopsy and peripheral blood counts according to the International Study of Aplastic Anemia and Agranulocytosis criteria; severity was classified by the criteria by Camitta et al.16 For the diagnosis of severe AA (sAA), in addition to a hypocellular BM without evidence of karyotypic abnormalities or morphologic dysplasia, patients fulfilled 2 of 3 blood criteria as previously described.16,19 Patients with AA, whose pancytopenia did not qualify as severe but with 2 of 3 blood parameters (absolute neutrophil count [ANC] < 1200, platelet count < 60 000/μL, and hemoglobin of < 8 g/dL), were classified as having moderate AA (mAA). When present, MDS was subclassified according to French-American-British (FAB) nomenclature and International Prognostic Scoring System (IPSS)17,18; hypocellular MDS was diagnosed if the overall biopsy cellularity was less than 25%. In general, the diagnosis of AA required exclusion of other pathologic conditions that can mimic its presentation. All bone marrow biopsies and aspirates were evaluated for morphology by an independent hematopathologist not associated with this study.

For the period between January 1989 and August 2001, we identified a total of 30 patients fulfilling the case definition criteria (Tables1 and2).

Table 1.

Clinical characteristics of patients

Initial
diagnosis
SexAgeCounts at presentationTreatments before
cytogenetic conversion
Response
to IST
ANC
× 103/μL
Hemoglobin
g/dL
Reticulocytes
× 103/μL
Platelets
× 103/μL
sAA 54 544 6.4 28 19 ATG/CsA, androgens NR 
sAA 77 48 10 3.8 11 ATG/CsA, GM-CSF R  
sAA 30 660 28 ATG/CsA, GM-CSF 
sAA 51 350 9.4 21 ATG/CsA, G-CSF NR 
sAA 42 288 7.6 12 ATG/CsA, G-CSF NR  
sAA 470 14 ATG/CsA, GM-CSF, G-CSF, SCF NR 
sAA 63 115 7.2 ATG/CsA, SCF/G-CSF NR 
sAA 73 870 9.6 28 13 ATG/CsA NR 
sAA 55 600 9.8 30 20 ATG/CsA, androgens 
10 sAA 11 450 10 65 ATG/CsA NR 
11 sAA 34 660 ATG/CsA 
12 sAA 20 230 ATG/CsA, SCF/G-CSF NR 
13 sAA 48 330 6.8 39 ATG/CsA 
14 sAA 45 1400 10 10 ATG/CsA 
15 sAA 49 666 9.8 47 ATG/CsA 
16 sAA 66 1000 5.4 32 ATG/CsA NR 
17 sAA 23 870 5.1 29 30 G-CSF/EPO NT 
18 sAA 67 1000 25 ATG/CsA 
19 sAA 43 360 9.5 23 ATG/CsA 
20 mAA 54 1080 6.9 40 14 ATG/CsA 
21 sAA 61 360 9.1 41 20 ATG/CsA 
22 sAA 61 120 3.5 14 15 ATG/CsA, SCF/G-CSF, EPO NR 
23 sAA 54 1068 8.2 24 ATG/CsA, SCF/G-CSF, androgens NR 
24 sAA 10 230 10 22 ATG/CsA, SCF/G-CSF, androgens NR 
25 sAA 16 774 19 18 ATG/CsA 
26 sAA 885 9.5 50 ATG/CsA 
27 sAA 48 820 21 18 CTX/CsA 
28 sAA 27 580 7.5 14 10 ATG/CsA 
29 mAA 53 1290 53 17 ATG/CsA 
30 sAA 34 494 7.5 32 16 ATG/CsA/MMF, ATG/CsA NR 
Initial
diagnosis
SexAgeCounts at presentationTreatments before
cytogenetic conversion
Response
to IST
ANC
× 103/μL
Hemoglobin
g/dL
Reticulocytes
× 103/μL
Platelets
× 103/μL
sAA 54 544 6.4 28 19 ATG/CsA, androgens NR 
sAA 77 48 10 3.8 11 ATG/CsA, GM-CSF R  
sAA 30 660 28 ATG/CsA, GM-CSF 
sAA 51 350 9.4 21 ATG/CsA, G-CSF NR 
sAA 42 288 7.6 12 ATG/CsA, G-CSF NR  
sAA 470 14 ATG/CsA, GM-CSF, G-CSF, SCF NR 
sAA 63 115 7.2 ATG/CsA, SCF/G-CSF NR 
sAA 73 870 9.6 28 13 ATG/CsA NR 
sAA 55 600 9.8 30 20 ATG/CsA, androgens 
10 sAA 11 450 10 65 ATG/CsA NR 
11 sAA 34 660 ATG/CsA 
12 sAA 20 230 ATG/CsA, SCF/G-CSF NR 
13 sAA 48 330 6.8 39 ATG/CsA 
14 sAA 45 1400 10 10 ATG/CsA 
15 sAA 49 666 9.8 47 ATG/CsA 
16 sAA 66 1000 5.4 32 ATG/CsA NR 
17 sAA 23 870 5.1 29 30 G-CSF/EPO NT 
18 sAA 67 1000 25 ATG/CsA 
19 sAA 43 360 9.5 23 ATG/CsA 
20 mAA 54 1080 6.9 40 14 ATG/CsA 
21 sAA 61 360 9.1 41 20 ATG/CsA 
22 sAA 61 120 3.5 14 15 ATG/CsA, SCF/G-CSF, EPO NR 
23 sAA 54 1068 8.2 24 ATG/CsA, SCF/G-CSF, androgens NR 
24 sAA 10 230 10 22 ATG/CsA, SCF/G-CSF, androgens NR 
25 sAA 16 774 19 18 ATG/CsA 
26 sAA 885 9.5 50 ATG/CsA 
27 sAA 48 820 21 18 CTX/CsA 
28 sAA 27 580 7.5 14 10 ATG/CsA 
29 mAA 53 1290 53 17 ATG/CsA 
30 sAA 34 494 7.5 32 16 ATG/CsA/MMF, ATG/CsA NR 

NR indicates nonresponsive; R, responsive; MMF, mycophenolate mofetil.

Table 2.

Clinical feature of cytogenetic evolution in AA

Time to
evolution
(mo)
First abnormal
karyotype
BM
cellularity
BM
morphology
Counts at conversionFABOutcome
ANC
× 103/μL
Hemoglobin
g/dL
Reticulocytes
× 103/μL
Platelets
× 103/μL
58 45,XY,−7[20] Hypo L-shift, dyserythopoiesis 320 9.1 19.7 RAEB Transfusion-dependent for red cells and platelets 
20 45,XY,−7[20] Hypo Megakaryocytes increased 500 20.3 80 RAEBt Temporary remission after chemotherapy  
72 45,XY,−7[20] Mixed L-shift, dysplastic megakaryocytes 250 13 51 129 RAEB MUD 
14 45,XY,−7[19]/46,XY[1] Hypo Megakaryocytes absent 850 7.4 53 RA Expired 
30 46,XX,t(2;3)(p23;q29)[2]/45XX,
idem,−7[20] 
Normo L-shift, dysplastic megakaryocytes 340 8.5 60 135 AML Expired 
97 45,XY,−7[14]/46,XY,−7,
+mar[7] 
Normo Myeloid dysplasia 390 8.5 37 AML Expired 
53 45,XY,−7[13]/45,idem,
del(12)(p12p13)[8] 
Mixed L-shift megakaryocytes decreased 160 9.4 12.6 15 AML Expired 
28 45,XY,−7[20] Mixed Dysplastic megakaryocytes 730 11.4 30.9 28 RAEB Expired 
47,XX,+8[3]/46,XX[14] Hyper Dysplastic megakaryocytes 900 45 20 RA Partial hematologic remission  
10 13 45,XY,−7[20] Hyper No dysplasia 550 7.5 18 22 RAEBt MUD, expired 
11 48 46,XX,+1,der(1;7)
(q10p10)[14]/46,XX[6] 
Normo L-shift, dysplasia 600 10 RAEBt MUD 
12 34 91,XXYY,−16[8]/91,XXYY,
del(6)(q15q25),−16[3]/
92,XXYY,del(6)(q15q25)[2]/
92,XXYY,del(5) 
Hyper L-shift 340 9.3 41 21 AML MUD 
13 47,XY,+8[18]/46,XY[2] Mixed Normal 1760 12 37 110 RA CsA-dependent counts 
14 38 47,XY,+8[20] Normo Normal 3300 13 90 130 RA CsA-dependent counts 
15 51 46,XX,del(13)(q12q14)[21]/
46,XX[4] 
Hyper Megaloblastic
changes 
2650 11.6 138 53 RA Stable counts 
16 45,X,−Y[5]/46,XY[15] Hypo L-shift 2450 8.8 63 35 RA Expired 
17 11 47,XX,+8[8]/45,XX,−5[3]/46,
XX[39] 
Hypo L-shift, megaloblastic changes 1800 9.9 78 41 RA GF therapy 
18 39 45,X,−Y[14] Normo L-shift 2000 8.6 107 37 RA CsA-dependent counts 
19 25 46,XY,del(13)(q12q14)[3]/46,
XY[17] 
Normo Normal 1900 10 63 118 RA Stable counts 
20 84 48,XXXc,+8[5]/47,XXXc[15] Hypo Megablastoid
changes 
1850 11 34 90 RA CsA-dependent counts 
21 17 46,XY,del20(q11.2q13.2)[9]/46,
XY[41] 
Hypo No dysplasia 1600 12 67 80 RA Stable counts 
22 116 47,XX,add(X)(p22.3),add(3)
(q26.2),+21 
Mixed L-shift 520 12 123 89 AML Expired 
23 34 46,XX,del(13)(q12q14)[4]/
46,XX[16] 
Hyper L-shift 1206 NA RAEB Transfusion-dependent for red cells and platelets 
24 126 45,XY,−7[7]/46,XY[13] Mixed Myeloid dysplasia 697 RAEBt MUD 
25 84 46,XX,del(17)(p11.2p13.1)[5]/
46,XX[47] 
Mixed L-shift, dysplastic megakaryocytes 1500 12 86 69 RA Stable counts 
26 20 46,XX,del(13)(q12q14)[4]/46,
XX[16] 
Mixed Normal 1052 7.9 20 20 RA CsA 
27 25 47,XY,+8[4]/46,XY[16] Hypo Normal 2700 11 69 56 RA CsA-dependent counts  
28 28 47,XY,+8[20] Hyper Dysplastic megakaryocytes 2290 15 NA 155 RA Stable remission 
29 47,XY,del(7)(p13p22)[3]/46,
XY[17] 
Hypo Normal 1350 15 47 48 RA CsA-dependent counts  
30 47,XY,+6[3]/46,46,XY[18] Hypo Normal, decreased megakaryocytes 1350 20 10 RA Transfusion-dependent for red cells and platelets 
Time to
evolution
(mo)
First abnormal
karyotype
BM
cellularity
BM
morphology
Counts at conversionFABOutcome
ANC
× 103/μL
Hemoglobin
g/dL
Reticulocytes
× 103/μL
Platelets
× 103/μL
58 45,XY,−7[20] Hypo L-shift, dyserythopoiesis 320 9.1 19.7 RAEB Transfusion-dependent for red cells and platelets 
20 45,XY,−7[20] Hypo Megakaryocytes increased 500 20.3 80 RAEBt Temporary remission after chemotherapy  
72 45,XY,−7[20] Mixed L-shift, dysplastic megakaryocytes 250 13 51 129 RAEB MUD 
14 45,XY,−7[19]/46,XY[1] Hypo Megakaryocytes absent 850 7.4 53 RA Expired 
30 46,XX,t(2;3)(p23;q29)[2]/45XX,
idem,−7[20] 
Normo L-shift, dysplastic megakaryocytes 340 8.5 60 135 AML Expired 
97 45,XY,−7[14]/46,XY,−7,
+mar[7] 
Normo Myeloid dysplasia 390 8.5 37 AML Expired 
53 45,XY,−7[13]/45,idem,
del(12)(p12p13)[8] 
Mixed L-shift megakaryocytes decreased 160 9.4 12.6 15 AML Expired 
28 45,XY,−7[20] Mixed Dysplastic megakaryocytes 730 11.4 30.9 28 RAEB Expired 
47,XX,+8[3]/46,XX[14] Hyper Dysplastic megakaryocytes 900 45 20 RA Partial hematologic remission  
10 13 45,XY,−7[20] Hyper No dysplasia 550 7.5 18 22 RAEBt MUD, expired 
11 48 46,XX,+1,der(1;7)
(q10p10)[14]/46,XX[6] 
Normo L-shift, dysplasia 600 10 RAEBt MUD 
12 34 91,XXYY,−16[8]/91,XXYY,
del(6)(q15q25),−16[3]/
92,XXYY,del(6)(q15q25)[2]/
92,XXYY,del(5) 
Hyper L-shift 340 9.3 41 21 AML MUD 
13 47,XY,+8[18]/46,XY[2] Mixed Normal 1760 12 37 110 RA CsA-dependent counts 
14 38 47,XY,+8[20] Normo Normal 3300 13 90 130 RA CsA-dependent counts 
15 51 46,XX,del(13)(q12q14)[21]/
46,XX[4] 
Hyper Megaloblastic
changes 
2650 11.6 138 53 RA Stable counts 
16 45,X,−Y[5]/46,XY[15] Hypo L-shift 2450 8.8 63 35 RA Expired 
17 11 47,XX,+8[8]/45,XX,−5[3]/46,
XX[39] 
Hypo L-shift, megaloblastic changes 1800 9.9 78 41 RA GF therapy 
18 39 45,X,−Y[14] Normo L-shift 2000 8.6 107 37 RA CsA-dependent counts 
19 25 46,XY,del(13)(q12q14)[3]/46,
XY[17] 
Normo Normal 1900 10 63 118 RA Stable counts 
20 84 48,XXXc,+8[5]/47,XXXc[15] Hypo Megablastoid
changes 
1850 11 34 90 RA CsA-dependent counts 
21 17 46,XY,del20(q11.2q13.2)[9]/46,
XY[41] 
Hypo No dysplasia 1600 12 67 80 RA Stable counts 
22 116 47,XX,add(X)(p22.3),add(3)
(q26.2),+21 
Mixed L-shift 520 12 123 89 AML Expired 
23 34 46,XX,del(13)(q12q14)[4]/
46,XX[16] 
Hyper L-shift 1206 NA RAEB Transfusion-dependent for red cells and platelets 
24 126 45,XY,−7[7]/46,XY[13] Mixed Myeloid dysplasia 697 RAEBt MUD 
25 84 46,XX,del(17)(p11.2p13.1)[5]/
46,XX[47] 
Mixed L-shift, dysplastic megakaryocytes 1500 12 86 69 RA Stable counts 
26 20 46,XX,del(13)(q12q14)[4]/46,
XX[16] 
Mixed Normal 1052 7.9 20 20 RA CsA 
27 25 47,XY,+8[4]/46,XY[16] Hypo Normal 2700 11 69 56 RA CsA-dependent counts  
28 28 47,XY,+8[20] Hyper Dysplastic megakaryocytes 2290 15 NA 155 RA Stable remission 
29 47,XY,del(7)(p13p22)[3]/46,
XY[17] 
Hypo Normal 1350 15 47 48 RA CsA-dependent counts  
30 47,XY,+6[3]/46,46,XY[18] Hypo Normal, decreased megakaryocytes 1350 20 10 RA Transfusion-dependent for red cells and platelets 

RA indicates refractory anemia; MUD, matched unrelated donor transplant.

Other studies performed

The presence of a PNH clone was determined historically by a Ham test or more recently using flow cytometry; the latter test was considered positive when more than 1% of glycosyl-phosphatidylinositol-anchored protein (GPI-AP)–deficient cells in blood were found as defined by negativity for surface staining for CD66b and CD16 in a distinctive population of cells.3Patients with the presence of PNH clone and otherwise fulfilling criteria of sAA or mAA were classified as having AA/PNH.

Therapy and response criteria

All but 2 patients received therapy with horse antithymocyte globulin (ATG; 40 mg/kg/d for 4 days) followed by 6 months of CsA adjusted to blood levels between 200 and 300 μg/L. One patient received 50 mg/kg cyclophosphamide for 4 days followed by CsA as initial therapy and one patient was treated only with a combination of growth factors (erythropoietin [EPO] and G-CSF). Six patients received 2 cycles of ATG. Several patients were also treated with granulocyte-macrophage colony-stimulating factor (GM-CSF) and stem cell factor (SCF; Table 1). The response to immunosuppression was determined 6 months after treatment and defined as transfusion independence for red cells and platelets and improvement in blood counts such that they no longer fulfilled severity criteria.19 

Statistical analysis

Means or medians (for nonnormal sample distribution) ± SD were calculated when appropriate. The unpaired Student ttest was applied to compare the means. For not normally distributed samples, an unpaired Wilcoxon test was used. Proportions were compared using χ2 test.

Demographic and clinical features of AA patients who developed abnormal karyotype

Patients who develop cytogenetic abnormalities in the course of AA have appeared to have heterogenous clinical characteristics and outcomes. To accurately address possible differences, we identified a large cohort of AA patients who had developed cytogenetic abnormalities. Loss of Y chromosome was observed in 2 patients and was included in this analysis but may be associated with aging, and its pathologic significance is not clear.29 Abnormalities involving chromosomes 7, 8, and 13 were most frequent among the group of 30 patients fulfilling case definition criteria (Tables 2 and3). All but 2 patients had presented with blood counts warranting a diagnosis of sAA; the remaining had mAA at presentation, which progressed to sAA. The average time from the initial diagnosis to cytogenic evolution was 39 ± 33 months (range, 5-126 months; Figure 1).

Table 3.

Frequency of cytogenetic abnormalities in AA

Karyotypic abnormalityAll other3-150
+8−73-150−13/−13q−Y
No. of patients 12 5  
% of total 23% 40% 13% 7% 16% 
Karyotypic abnormalityAll other3-150
+8−73-150−13/−13q−Y
No. of patients 12 5  
% of total 23% 40% 13% 7% 16% 
F3-150

Structural and numerical abnormalities of chromosome 7.

Fig. 1.

Differential prognosis in AA patients who developed cytogenetic abnormalities.

(A) Cytogenetic evolution over the time within the group (30 patients = 100%). (B) Survival from the time of diagnosis (n = 30). (C) Survival from the time of evolution (n = 30). (D) Survival of patients with trisomy 8 (Tri-8; n = 7) and abnormalities of chromosome 7 (Mono-7; n = 11; P = .075).

Fig. 1.

Differential prognosis in AA patients who developed cytogenetic abnormalities.

(A) Cytogenetic evolution over the time within the group (30 patients = 100%). (B) Survival from the time of diagnosis (n = 30). (C) Survival from the time of evolution (n = 30). (D) Survival of patients with trisomy 8 (Tri-8; n = 7) and abnormalities of chromosome 7 (Mono-7; n = 11; P = .075).

Close modal

The mean age of AA patients who developed karyotypic abnormalities was 42 years (range, 8-77 years) with a male-to-female ratio of 16:14. At presentation of AA, the mean platelet count was 13 900/μL (range, 2000-39 000/μL); ANC was 488/μL (range, 48-1400/μL); and the mean reticulocyte count (ARC) and hemoglobin concentration were 23 000/μL (range, 3000-65 000/μL) and 7.3 g/dL (range, 6-10 g/dL), respectively (Table 1). Clinically, of 29 patients treated with IST, 28 had received ATG/CsA and 1 had received cyclophosphamide and CsA in combination. Thirteen patients did not respond to immunosuppression and 16 did respond (54%). In addition, prior to cytogenetic evolution, 6 patients received therapy with SCF combined with G-CSF, 1 patient received EPO and G-CSF as long-term primary therapy, 2 patients received GM-CSF, and another 3 received G-CSF as a supportive therapy prior to and after IST (Table 1). After transformation to MDS, therapies included androgens, G-CSF, and some patients (see below) continued CsA.

All patients were tested for the presence of a PNH clone. In 21 cases assessed by flow cytometry, 12 had detectable GPI-AP–deficient granulocytes (57%), and in another 2 patients in whom flow cytometry was not performed, the presence of PNH was established by the Ham test. The prevalence of PNH in this group of patients was at least 50% and not statistically different from an historical cohort of AA (38% at presentation, 35% 1-4 years, and 50% in patients with > 4 years disease duration). There were no additional conversions to PNH within this group observed after cytogenetic evolution.

Clinical features and outcomes of clonal evolution in AA

In total, in comparison to initial presentation, there was a trend to higher blood counts at the time of diagnosis of clonal evolution (mean ANC of 1263/μL; range, 160-3300/μL), mean platelet count of 54 000/μL (range, 5000-155 000/μL), and mean hemoglobin concentration and ARC of 9.9 g/dL (range, 7-15 g/dL) and 52 000/μL (range, 7 000-13 800/μL), respectively; however, the individual blood counts depended on the response status to initial immunosuppression (see below). Marrow morphology was characterized by predominance of hypercellularity (41%) and patchy biopsy cellularity (27%), although continued hypocellularity was found in 1 of 3 of the patients. Frank dysplasia, including changes in megakaryocyte morphology, were found in 15 of 30 patients, and a left shift in myeloid differentiation was observed in 12. However, in 9 of 30 patients, there were no morphologic changes suggestive of MDS.

AA patients who developed secondary chromosomal abnormalities showed a mortality rate of about 27% with mean follow-up after evolution of 29 months (from the initial diagnosis, the total observation interval was 70 months; Figure 1). All but 2 deaths were related to complications of leukemia. In total, 13 patients (45%) developed either refractory anemia with excess blasts in transformation (RAEBt) or acute myeloid leukemia (AML; Table 2). Of these patients, 5 underwent unrelated matched BM transplantation.

Of the 30 patients, totally clonal hematopoiesis (100% of affected metaphases) was present at initial cytogenetic diagnosis in 13 patients. In all but 2 patients who initially presented with a mosaic of normal and abnormal karyotype, there was a steady increase in percentages of karyotypically abnormal metaphases during the observation interval. Disappearance of an abnormal clone was observed only in 2 patients, in both of whom, at evolution, only 20% to 25% cytogenetically abnormal metaphases were counted.

Abnormal karyotypes—clinical comparisons

Among patients who developed karyotypic abnormalities, trisomy 8 (n = 7; 23% of total) and partial or total loss of chromosome 7 (n = 12; 40% of total; Table 3) were most common. We have compared the clinical features of these 2 groups of patients (Table4). There were no significant differences between their ages at presentation of AA, time to evolution of cytogenetic abnormality, or blood counts at presentation (AA patients who later developed monosomy 7 showed a trend to a lower initial ANC). There was an obvious difference in initial responsiveness to IST. Among 6 patients with trisomy 8 treated with immunosuppression, all had responded to ATG and CsA and their blood counts continued to be dependent on CsA therapy. For patients with other cytogenetic abnormalities, similar CsA dependence of blood counts was observed only in 2 cases (1 patient with a transient 7p− and another with −Y). When compared with patients with numerical or structural defects of chromosome 7 at diagnosis of abnormal karyotype, those with trisomy 8 showed significantly higher mean ANC, hemoglobin concentration, and mean reticulocyte and platelet counts at the time of chromosomal evolution (Table 4).

Table 4.

Comparison of clinical features of trisomy 8 and monosomy 7

AbnormalityP
−74-154+8
114-150  
Age (y) 41 ± 24 42 ± 12 .87 
Time to evolution (mo) 47 ± 36 28 ± 25 .21 
Mortality (%) 50% 0% .0894-151 
Initial blood counts    
 ANC × 103/μL 425 ± 250 811 ± 354 .0152 
 Hemoglobin (g/dL) 7.2 ± 2.6 8 ± 1.7 .48 
 Reticulocytes × 103/μL 18 ± 18 21 ± 12 .67 
 Platelets × 103/μL 12 ± 5 18 ± 11 .11  
Blood counts at evolution    
 ANC × 103/μL 489 ± 217 2085 ± 768 .0001 
 Hemoglobin (g/dL) 8.8 ± 1.8 11.4 ± 2.2 .0169 
 Reticulocytes × 103/μL 29 ± 18 58 ± 23 .0114 
 Platelets × 103/μL 40 ± 50 86 ± 49 .07 
Response of AA to IST (%) 25% 100% .0134-151 
AbnormalityP
−74-154+8
114-150  
Age (y) 41 ± 24 42 ± 12 .87 
Time to evolution (mo) 47 ± 36 28 ± 25 .21 
Mortality (%) 50% 0% .0894-151 
Initial blood counts    
 ANC × 103/μL 425 ± 250 811 ± 354 .0152 
 Hemoglobin (g/dL) 7.2 ± 2.6 8 ± 1.7 .48 
 Reticulocytes × 103/μL 18 ± 18 21 ± 12 .67 
 Platelets × 103/μL 12 ± 5 18 ± 11 .11  
Blood counts at evolution    
 ANC × 103/μL 489 ± 217 2085 ± 768 .0001 
 Hemoglobin (g/dL) 8.8 ± 1.8 11.4 ± 2.2 .0169 
 Reticulocytes × 103/μL 29 ± 18 58 ± 23 .0114 
 Platelets × 103/μL 40 ± 50 86 ± 49 .07 
Response of AA to IST (%) 25% 100% .0134-151 

Statistical analysis: t test (normal distribution) or Wilcoxon test when appropriate.

F4-150

Patient with a transient abnormality not included.

F4-151

χ2 test.

F4-154

Numerical and structural abnormalities.

The prognosis of patients with abnormalities of chromosome 7 appear much worse in comparison to those with trisomy 8 (Figure 1); although all patients with trisomy 8 remain alive and had not progressed to leukemia over a mean observation interval of 44 months (range, 5-84 months), those patients who developed numerical or structural chromosome 7 aberrancy showed high rates of mortality (50%) and transformation (RAEBt and AML in 6 of 11). Two patients who developed complex karyotypic abnormality also progressed to RAEBt or AML.

Our report differs from previously published summaries in the large numbers of patients examined and the exclusion of cases in whom cytogenetics were abnormal at presentation of marrow failure. AA patients with true evolution of karyotypic changes were clinically diverse, and their prognosis was strongly linked to the type of cytogenetic defect. In agreement with other published data,5,8,14,15 the most common cytogenetic abnormalities were aberrations of chromosome 7 and trisomy 8; in a study from Seattle, monosomy 7 was found in 3 and trisomy 8 in 2 of 7 patients with karyotypic abnormalities,5 in a Dutch series, in 3 of 5 patients who evolved to MDS from AA,14 whereas among Italian patients,8 trisomy 8 was most frequent, present in 8 of 18 cases, followed by monosomy 7 in 2 of 18 patients (only a minority of these patients had initially normal cytogenetics at the time of presentation). In contrast to these results and to our own data, a recent meta-analysis showed trisomy 6 as most common in AA,20 but in all of the patients included in this study, the abnormal karyotype was present at initial diagnosis.

The appearance of a cytogenetic abnormality in a patient with AA provides strong evidence of clonal evolution to MDS. However, a high proportion of transient chromosomal changes, as reported in some studies, would diminish the diagnostic and prognostic implications of new cytogenetic defects. The low incidence of this finding in our study may be due to the stringent exclusion of patients who showed abnormal cytogenetics at presentation.

Myelodysplasia evolving from AA and primary MDS differ in the distribution of specific cytogenetic abnormalities. In primary MDS, abnormalities of chromosome 5 are most frequent (10%-37% of patients),21-28 but this chromosome is only occasionally affected in AA. 20q− is also found more often in primary MDS in comparison to AA.21,22 Conversely, monosomy 7, most prominent in late evolution of MDS from AA, occurs in a minority of primary MDS, 6.5% to 11%.20-27 Trisomy 8 appears to have a comparable incidence among cytogenetic abnormalities evolving from AA and in primary MDS, 6% to 20%.21-28 In MDS, the prevalence of patients with normal karyotypes ranges from 31% to 60%.17,21-23,25,27 Except for the evolution to leukemia or RAEBt, diagnosis of MDS with normal karyotype in the context of AA is hampered by many subjective factors and was not a subject of this study.

Cytogenetic abnormalities are strong predictors of clinical behavior and survival in acute and chronic leukemias,30,31 multiple myeloma,32 and primary MDS.18 In our series, in agreement with the IPSS classification for primary MDS,18 there was a major difference in prognosis of patients who developed defects of chromosome 7 or who had complex karyotypic abnormalities; these lesions were present in all of our patients who died or developed leukemia. In retrospect, these patients usually had had treatment-refractory and persistent pancytopenia. In contrast, trisomy 8 and other prognostically more benign abnormalities were frequent in the context of a good hematologic response to immunosuppression, and even after evolution to trisomy 8, improved blood counts were often dependent on continued CsA administration. Blood counts of patients at the time of cytogenetic evolution to trisomy 8 were significantly higher than those of patients with monosomy 7. The prognosis of trisomy 8 in primary MDS is not entirely favorable, with survival comparable to that of monosomy 7.25-28 Trisomy 8 is found in more advanced FAB subtypes, often included in the intermediate-risk group with average survival of 2.4 years (17.2 months in an analysis of 115 patients with trisomy)8,26 and time to evolution of AML of 1.6 years.18 The sharp contrast of this observation with the clinical course and prognosis of trisomy 8 evolving from AA suggests a different biology for an apparently identical cytogenetic abnormality in late AA and in primary MDS. Patients with abnormalities of chromosome 7 in AA fared as poorly as in primary MDS, with a high rate of conversion to acute leukemia.18,27 

Fundamental questions in the evolution of clonal disease in AA are whether its pathophysiology is intrinsic to the natural history of AA, and now only observed as patients survive longer due to effective therapy, or secondary as a complication of, for example, immunosuppression,13 or chronic growth factor administration. However, MDS has occurred in AA treated with androgens only9,33 and though prolonged G-CSF treatment was linked by Japanese investigators to evolution of monosomy 7,11,34,35there was no increased risk observed in a randomized study of ATG and CsA with and without G-CSF36 or in an analysis of data from the European Group for Blood and Marrow Transplantation.37Many of our patients received hematopoietic growth factors, mainly as support or salvage therapy, and refractory disease itself may be the underlying risk factor for clonal evolution. Most AA patients who did not undergo BM transplantation will be treated with immunosuppression and hematopoietic growth factors, and in the absence of appropriate control groups, it is difficult to rigorously establish or exclude a pathophysiologic relationship between clonal evolution and therapy.

The relationship between AA, a disease dominated by an immune pathophysiology, and MDS, usually viewed as a premalignant process, remains unclear both clinically and pathophysiologically. In historical studies of abnormal karyotypes in AA, patients with abnormal cytogenetics and hypoplastic marrows at presentation were often included,6-10 and in some institutions, abnormal cytogenetics are compatible with a primary diagnosis of AA.7-9,20 In our series, our case definition was more stringent; cytogenetics were normal at first presentation, and most abnormal cytogenetic findings occurred after multiple normal studies. Whether more sensitive methods, such as fluorescent in situ hybridization, would have disclosed small populations of aberrant cells at earlier time points remains a moot question but a subject of current research. Were underdiagnosis due to inadequate techniques for the detection of chromosomal changes important, a more rapid evolution to MDS might be anticipated, but in our experience, chromosomal changes emerged gradually over time, more consistent with stochastic kinetics than a determinative process. Clinically, karyotypic abnormalities appear to concur with other features of typical AA such as the high incidence of HLA-DR238,39 and coexistence of an expanded PNH clone3; patients who show cytogenetic evolution do not obviously belong to a distinct nosologic subtype, as might be expected with primary misdiagnosis of MDS. Nevertheless, some of the same laboratory features have been reported in primary MDS.40For clinicians, the distinction between AA and hypocellular MDS ultimately may depend on empiric observations of the behavior associated with specific cytogenetic patterns. Monosomy 7 should continue to be regarded as itself a dire event, but for trisomy 8, the cytogenetic abnormality does not alter the desirability of an aggressive immunologic approach to improve the function of an empty BM.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Young
NS
Barrett
AJ
The treatment of severe acquired aplastic anemia.
Blood.
95
1995
3367
3377
2
Dunn
DE
Tannawattanacharoen
P
Boccuni
P
et al
Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes.
Ann Intern Med.
131
1999
401
408
3
Maciejewski
JP
Rivera
C
Dunn
D
Young
NS
Clinical features of the relationship between aplastic anemia and paroxysmal nocturnal hemoglobinuria.
Br J. Hematol.
115
2001
1015
1022
4
Tichelli
A
Gratwohl
A
Wursch
A
et al
Late hematologic complications in severe aplastic anemia.
Br J Haematol.
69
1988
413
418
5
Doney
K
Leisenring
W
Storb
R
Appelbaum
FR
Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy.
Ann Intern Med.
126
1997
107
115
6
Socie
G
Rosenfeld
S
Frickhofen
N
Gluckman
E
Tichelli A. Late clonal complications of aplastic anemia.
Semin Hematol.
37
2000
91
101
7
Geary
CG
Harrison
CJ
Philpott
NJ
Hows
JM
Gordon-Smith
EC
Marsh
CW
Abnormal cytogenetic clone in patients with aplastic anemia: response to immunosuppressive therapy.
Br J Hematol.
104
1999
271
274
8
Mikhailova
N
Sesserego
M
Fugazza
G
et al
Cytogenetic abnormalities in patients with severe aplastic anemia.
Haematologica.
81
1996
418
422
9
Appelbaum
F
Barrall
J
Storb
R
et al
Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia.
Exp Hematol.
5
1987
1134
1139
10
De Planque
MM
Baciagalupo
A
Wursch
A
et al
Long-term follow up of severe aplastic anemia patients treated with antithymocyte globulin.
Br J Hematol.
73
1989
121
126
11
Yamazaki
E
Kanamori
H
Taguchi
J
Harano
H
Mohri
H
Okubo
T
The evidence for clonal evolution with monosomy 7 in aplastic anemia following granulocyte colony-stimulating factor using the polymerase chain reaction.
Blood Cells Mol Dis.
23
1997
213
218
12
Plaquette
RL
Tebyani
N
Frane
M
et al
Long-term outcome of aplastic anemia in adults treated with anti-thymocyte globulin: comparison with bone marrow transplantation.
Blood.
85
1996
283
290
13
Socie
G
Henryamar
M
Bacigalupo
A
Malignant tumors occurring after treatment of aplastic anemia.
N Engl J Med.
329
1993
1152
1157
14
De Planque
MM
Kluin-Nelemans
HC
van Kierken
HJ
et al
Evolution of acquired severe aplastic anemia to myelodysplasia and subsequent leukemia in adults.
Br J Haematol.
70
1988
55
62
15
Jameel
T
Anwar
M
Abdi
SI
Saleem
M
Ahmad
PA
Khattak
MF
Aplastic anemia or aplastic preluekemic syndrome?
Ann Hematol.
75
1997
189
193
16
Camitta
BM
Thomas
ED
Nathan
DG
et al
Severe aplastic anemia: a prospective study of the effect of early bone marrow transplantation on acute mortality.
Blood.
48
1976
63
70
17
Bennett
JM
Catovsky
D
Daniel
MT
et al
Proposal for the classification of the myelodysplastic syndromes.
Br J Hematol.
51
1986
181
199
18
Greenberg
P
Cox
Ch
LeBeau
M
et al
International scoring system for evaluating prognosis in myelodysplastic syndromes.
Blood.
89
1997
2079
2088
19
Rosenfeld
SJ
Kimball
J
Vining
D
Young
NS
Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia.
Blood.
85
1995
3058
3065
20
Yi-Kong
Keung
Pettenati
MJ
Cruz
JM
Powell
BL
Woodruff
RD
Buss
DH
Bone marrow cytogenetic abnormalities of aplastic anemia.
Am J Hematol.
66
2001
167
171
21
Michalova
K
Musilova
J
Zemanova
Z
Cytogenetic abnormalities in 532 patients with myeloid leukemias and myelodysplastic syndrome. The Czechoslovak MDS Cooperative Group.
Czech Med.
13
1999
133
144
22
Vila
L
Charrin
C
Archimbaud
E
Treille-Ritouet
D
et al
Correlations between cytogenetics and morphology in myelodysplastic syndromes.
Blut
60
1990
223
227
23
Bernasconi
P
Alessandrino
EP
Boni
M
et al
Karyotype in myelodysplastic syndrome: relations to morphology, clinical evolution and survival.
Am J Hematol.
46
1994
270
277
24
Knapp
RH
Dewald
GW
Pierre
RV
Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes.
Mayo Clin Proc.
60
1985
507
516
25
Succiu
S
Kuse
R
Weh
HJ
Hossfeld
DK
Results of chromosome studies and their relation to morphology, course and prognosis in 120 patients with de novo myelodysplastic syndrome.
Cancer Genet Cytogenet.
44
1990
15
26
26
Pedersen
B
MDS and AML with trisomy 8 as a sole chromosome aberration show different sex ratios and prognostic profiles: a study of 115 published cases.
Am J Hematol.
56
1997
224
229
27
Sole
F
Espinet
B
Sanz
GF
et al
Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes.
Br J Hematol.
108
2000
346
356
28
Sousa de Feranadez
T
Ornellas
MH
Otero de Carvalho
L
Tabak
D
Abdelhay
E
Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia.
Leuk Res.
24
2000
839
848
29
Wiktor
A
Rybicki
BA
Piao
ZS
et al
Clinical significance of Y chromosome loss in hematologic disease.
Genes Chromosomes Cancer.
27
2000
11
16
30
Grimwalde
D
Walker
H
Oliver
F
et al
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial.
Blood.
92
1998
2322
2333
31
Slovak
ML
Kopecky
KJ
Cassileth
PA
et al
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study.
Blood.
96
2000
4075
4083
32
Fonseca
R
Coignet
LJ
Dewald
GW
Cytogenetic abnormalities in multiple myeloma.
Hematol Oncol Clin North Am.
13
1999
1169
1180
33
Varma
N
Varma
S
Movafagh
A
Gareval
G
Unusual clonal cytogenetic abnormalities in aplastic anemia [letter].
Am J Hematol.
49
1995
256
257
34
Ohara
A
Kojima
S
Hamajima
N
Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia.
Blood.
90
1997
1009
1013
35
Kaito
K
Kobayashi
M
Katayama
T
et al
Long-term administration of G-CSF for aplastic anemia is closely related to the early evolution of monosomy 7 MDS in adults.
Br J Hematol.
103
1998
297
303
36
Kojima
S
Hibi
S
Kosaka
Y
et al
Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia.
Blood.
96
2000
2049
2054
37
Bacigalupo
A
Brand
R
Oneto
R
et al
Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy. The European Group for Blood and Marrow Transplantation experience.
Semin Hematol.
37
2000
69
80
38
Nimer
SD
Ireland
P
Meshkinpour
A
Frane
M
An increased HLA DR2 frequency is seen in aplastic anemia patients.
Blood.
84
1994
923
927
39
Maciejewski
JP
Follmann
D
Rivera
CE
Simonis
T
Young
NS
Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and PNH/aplastic anemia syndrome.
Blood.
98
2001
3513
3519
40
Young NS, Barrett AJ. Immune modulation of myelodysplasia: rationale and therapy. In: Bennett JM, ed. The Myelodysplastic Syndromes: Pathobiology and Clinical Management. New York, NY: Marcel Dekker. In press.

Author notes

Jaroslaw P. Maciejewski, Hematopoiesis and Experimental Hematology Section, Cleveland Clinic Taussig Cancer Center, 9500 Euclid Ave, Cleveland, OH 44195; e-mail:maciejj@cc.ccf.org.